Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1557|24|11|1121-1132

ISSN： 1053-8569

Source： PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol.24, Iss.11, 2015-11, pp. : 1121-1132

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non–Rheumatoid Arthritis Patients

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 8, 2015-05 ,pp. : 2004-2010

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Patient-Centered Approach to Detecting Harm in Adverse Drug Events

By Hunt David R.  

Joint Commission Journal on Quality and Patient Safety, Vol. 36, Iss. 1, 2010-01 ,pp. : 10-11

Joint Commission Resources

Access to resources Recommend Favorite

The burden of adverse drug events

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 4, 2015-10 ,pp. : 785-787

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNF Drug

By  

Current Drug Safety, Vol. 1, Iss. 3, 2006-08 ,pp. : 259-264

Bentham Science Publishers

Access to resources Recommend Favorite

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 11, 2015-11 ,pp. : 1529-1535

John Wiley & Sons Inc

Access to resources Recommend Favorite